brain-penetrant mutant ALK kinase inhibitor

oral, Ph. I/II in ALK+ pre-treated cancers

undisclosed starting point, SBDD

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, US

TPX-0131

2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK inhibitors against WT-ALK and many ALK resistance mutations, including…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: